Evidence map›Paper›PMID 40676524›Full record

ArticleBMC neurology2025

Extracorporeal therapy procedures (plasma exchange and immunoadsorption) in chronic inflammatory demyelinating polyneuropathies (CIDP)- a database analysis.

Moritz Mahlberg, Johannes Dorst, Zeynep Elmas, Ulrike Haase, Michael Heming, Louisa Müller-Miny, Gerd Meyer Zu Hörste, Mark Stettner, Florian Then Bergh, Petra Baum and 1 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Moritz MahlbergDepartment of Neurology, University of Leipzig, Leipzig, Germany. moritz.mahlberg@gmail.com.
Johannes DorstDepartment of Neurology, University of Ulm, Ulm, Germany.
Zeynep ElmasDepartment of Neurology, University of Ulm, Ulm, Germany.
Ulrike HaaseDepartment of Neurology, Heinrich-Braun-Klinikum Zwickau, Zwickau, Germany.
Michael HemingDepartment of Neurology with Institute of Translational Neurology, Medical Faculty, University Hospital Münster, Münster, Germany.
Louisa Müller-MinyDepartment of Neurology with Institute of Translational Neurology, Medical Faculty, University Hospital Münster, Münster, Germany.
Gerd Meyer Zu HörsteDepartment of Neurology with Institute of Translational Neurology, Medical Faculty, University Hospital Münster, Münster, Germany.
Mark StettnerDepartment of Neurology, Working Group for Clinical and Experimental Neuroimmunology, University Hospital Essen, Essen, Germany.
Florian Then BerghDepartment of Neurology, University of Leipzig, Leipzig, Germany.
Petra BaumDepartment of Neurology, University of Leipzig, Leipzig, Germany.
Disease-Related Competence Network Peripheral Nervous System (KKPNS)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesThere is limited study data on both therapeutic plasma exchange (PE) and immunoadsorption (IA) in chronic inflammatory demyelinating polyneuropathy (CIDP), mostly based on case series in patients in the early stages of the disease. The aim of this retrospective study was to compare the efficacy and tolerability of the two therapy procedures in a larger sample with a longer duration of disease and immunomodulatory pre-treatment.

methodsIn this retrospective study from 5 centers in Germany, register data on the efficacy, safety and tolerability of therapy with IA or PE in patients with CIDP were examined. Treatment response was assessed using neurological scores (INCAT and Hughes Score), duration of hospital stay, and subjective assessment by examiners and patients. In addition, side effects were recorded.

resultsA total of 44 patients were analyzed, 23 treated with PE (mean age 61.3 years, 17 male, 6 female) and 21 with IA (mean age 67, 14 male, 7 female). The mean duration of disease before treatment was 8.48±3.82 years (PE group) and 7.24±3.15 years (IA group). IA and PE showed a comparable treatment response. With IA, 11 out of 21 (52.4%) patients improved, whereas with PE, 14 out of 23 (60.9%) patients improved. The differences between before- and after-treatment INCAT and Hughes scores also showed an improvement with both PE and IA individually (INCAT 1.17±1.61 and 0.71±1.65, respectively, Hughes score 0.48±0.73 and 0.33±0.66, respectively), while there were no significant differences between the two groups. The patients in the IA group had a significantly shorter inpatient stay (p < 0.019). There was one adverse event in each group, but no serious adverse events in either group. DISCUSSION: This retrospective study indicates that IA and PE show comparable efficacy in chronic autoimmune neuropathies, including patients with longer disease duration and immunomodulatory pretreatment.

Indexed as

Immunosorbent TechniquesPlasma ExchangePolyradiculoneuropathy, Chronic Inflammatory DemyelinatingAgedDatabases, FactualFemaleGermanyHumansMaleMiddle AgedRetrospective StudiesTreatment Outcomechronic inflammatory demyelinating polyneuropathy, neurological autoimmune diseases, immunoadsorption, plasma exchange, treatment, INCAT score, Hughes score

Identifiers

PMID40676524
PMCPMC12273229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.